Tesamorelin reduces liver fat and fibrosis progression in people with HIV and non-alcoholic fatty liver disease
Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease, researchers report in the journal The Lancet HIV this month. Non-alcoholic fatty liver disease (NAFLD) – the accumulation of fat in the liver – is a… Read More »